Trial · NCT03114995
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
NCT03114995, Phase 4, Completed, Seoul National University Bundang Hospital; results first posted 2018-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients. Trials, record NCT03114995. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03114995
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
- NCT number
- NCT03114995
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 140 participants, actual
- Lead sponsor
- Seoul National University Bundang Hospital
- Conditions
- Non-ST Elevation Myocardial Infarction
- Interventions
- Tirofiban
- First posted
- 2017-04-14
- Last updated
- 2018-07-17
- Results first posted
- 2018-06-08
- Limitations and caveats
- The difference in the distribution of PRU values of subjects estimated from previous literatures leading to small numbers of subjects assigned to the study group
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Area Under Curve of Serial Cardiac Biomarkers | 0,6,12,18,24,30,36 hours | An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours |
| Secondary | Percentage of Participants With Periprocedural Myonecrosis | 0,6,12,18,24,30,36 hours | Percentage of participants with periprocedural myonecrosis under the criteria described below. When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Area Under Curve of Serial Cardiac Biomarkers | 0,6,12,18,24,30,36 hours | Hours*ng/ml | MEDIAN | |
| SECONDARY | Percentage of Participants With Periprocedural Myonecrosis | 0,6,12,18,24,30,36 hours | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under Curve of Serial Cardiac Biomarkers | Group A (High Platelet Reactivity - Tirofiban) | Troponin I | 197.2 | Inter-Quartile Range 41.5 to 395.7 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C1 (High Platelet Reactivity - no Tirofiban) | Troponin I | 38.0 | Inter-Quartile Range 8.9 to 313.9 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C2 (Low Platelet Reactivity - no Tirofiban) | Troponin I | 121.4 | Inter-Quartile Range 43.7 to 481.8 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Group A (High Platelet Reactivity - Tirofiban) | creatine kinase-MB isoenzyme | 252.5 | Inter-Quartile Range 48.0 to 470.1 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C1 (High Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 92.7 | Inter-Quartile Range 39.1 to 402.1 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C2 (Low Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 185.6 | Inter-Quartile Range 79.8 to 425.3 | Hours*ng/ml |
| Percentage of Participants With Periprocedural Myonecrosis | Group A (High Platelet Reactivity - Tirofiban) | Troponin I | 16 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C1 (High Platelet Reactivity - no Tirofiban) | Troponin I | 15 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C2 (Low Platelet Reactivity - no Tirofiban) | Troponin I | 26 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Group A (High Platelet Reactivity - Tirofiban) | creatine kinase-MB isoenzyme | 11 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A (High Platelet Reactivity - Tirofiban) | 31 | |
| Overall Study | STARTED | Control C1 (High Platelet Reactivity - no Tirofiban) | 31 | |
| Overall Study | STARTED | Control C2(Low Platelet Reactivity - no Tirofiban) | 78 | |
| Overall Study | COMPLETED | Group A (High Platelet Reactivity - Tirofiban) | 30 | |
| Overall Study | COMPLETED | Control C1 (High Platelet Reactivity - no Tirofiban) | 30 | |
| Overall Study | COMPLETED | Control C2(Low Platelet Reactivity - no Tirofiban) | 78 | |
| Overall Study | NOT COMPLETED | Group A (High Platelet Reactivity - Tirofiban) | 1 | |
| Overall Study | NOT COMPLETED | Control C1 (High Platelet Reactivity - no Tirofiban) | 1 | |
| Overall Study | NOT COMPLETED | Control C2(Low Platelet Reactivity - no Tirofiban) | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Minor bleeding | Blood and lymphatic system disorders | Group A (High Platelet Reactivity - Tirofiban) | 4 | 30 | 4 |
| other | Minor bleeding | Blood and lymphatic system disorders | Control C1 (High Platelet Reactivity - no Tirofiban) | 1 | 30 | 1 |
| other | Minor bleeding | Blood and lymphatic system disorders | Control C2 (Low Platelet Reactivity - no Tirofiban) | 8 | 78 | 8 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A (High Platelet Reactivity - Tirofiban) | 2 | 30 |
| Total, all-cause mortality | Control C1 (High Platelet Reactivity - no Tirofiban) | 0 | 30 |
| Total, all-cause mortality | Control C2 (Low Platelet Reactivity - no Tirofiban) | 0 | 78 |
| Total, other adverse events | Group A (High Platelet Reactivity - Tirofiban) | 4 | 30 |
| Total, other adverse events | Control C1 (High Platelet Reactivity - no Tirofiban) | 1 | 30 |
| Total, other adverse events | Control C2 (Low Platelet Reactivity - no Tirofiban) | 8 | 78 |
| Total, serious adverse events | Group A (High Platelet Reactivity - Tirofiban) | 0 | 30 |
| Total, serious adverse events | Control C1 (High Platelet Reactivity - no Tirofiban) | 0 | 30 |
| Total, serious adverse events | Control C2 (Low Platelet Reactivity - no Tirofiban) | 0 | 78 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03114995
GET https://conductscience.org/api/trials/v1/NCT03114995/registered